Research

In addition to these papers, the INRG Task Force has published consensus papers, available here.

Click on a description for the original article or project details.

INRG Project Number Investigators Description Publication/Abstract
2020-03 Bao R, Desai AV, Cohn SL Validation of a T-cell inflammatory signature and outcomes in patients with
neuroblastoma

Project underway

2020-02 Skapek S,  Xu L, Cohn S, Applebaum M Identifying neuroblastoma drivers and bringing them to the clinic

Project underway

2020-01 Pudela C, Desai A, Applebaum M, Henderson T, Cohn S Racial and Ethnic Disparities in Risk and Survival in Children With Neuroblastoma: An Updated Analysis Using the International Neuroblastoma Risk Group Database Presented at ASCO 2021
2019-04 Mayampurath A, Volchenboum S, Cohn S, Applebaum M Predicting induction chemotherapy response using deep learning Presented at ASCO 2021
2019-03 Angelini P, Vaidya S, Okoye B, Pearson A, London W Ganglioneuroma (GN) and Intermixed ganglioneuroblastoma (iGNB): characteristics at diagnosis, natural history and outcome. Presented at ANR 2021
2019-02 Balyasny S, Applebaum, M, Cohn SL, Desai A Evaluation of the Effect of Trial Participation on Outcomes for Intermediate and High-Risk Neuroblastoma Patients Project underway
2019-01 Vo K Pattern and predictors of sites of relapse in neuroblastoma Project underway
2018-01 Moreno L, London W, Morgenstern D, Schleiermacher G, Irwin M International integrated analysis to identify markers of poor survival in high-risk neuroblastoma Project underway
2017-04 Sokol E, Desai AV, Applebaum MA, Shimada H, Valteau-Couanet D, Park JR, Pearson ADJ, Schleiermacher G, Irwin MS, Hogarty M, Naranjo A, Volchenboum S, Cohn SL, London WB Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An International Neuroblastoma Risk Group (INRG) project J Clin Oncol. 2020 Apr 21. doi: 10.1200/JCO.19.03285
2017-02 Greengard E, London WB Gender as a prognostic indicator in neuroblastoma Project underway
2017-01 Campbell K, Shyr D, Bagatell R, Fischer M, Nakagawara A, Nieto AC, Brodeur GM, Matthay KK, London WB, DuBois SG Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project Pediatr Blood Cancer. 2019 Aug;66(8):e27819. doi: 10.1002/pbc.27819
2016-01 Moreno L, Cohn SL, Pearson ADJ, Guo D, Owens C, Irwin MS, Berthold F, Hogaryt M, Kamijo T, Valteau-Couanet D and London WB Analysis of late relapses in high-risk neuroblastoma patients Project underway
2015-01 Moreno L, Pearson ADJ, Guo D, Morgenstern D, Pasqualini C, Ash S, Valteau-Couanet D, Cohn SL, London WB Predicting early relapse/progression death in children with stage M neuroblastoma
Pediatr Blood Cancer. 2020 Nov 18;e28794. doi: 10.1002/pbc.28794
2014-04 Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting J Clin Oncol. 2017 Aug 1;35(22):2580-2587. doi: 10.1200/JCO.2016.72.0177. Epub 2017 May 4.
2014-03 Thompson D, Vo KT, London WB, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK, DuBois SG Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Cancer. 2016 Mar 15;122(6):935-45.
2014-02 Applebaum MA, Vaksman Z, Lee SM, Hungate EA, Henderson TO, London WB, Pinto N, Volchenboum SL, Park JR, Naranjo A, Hero B, Pearson AD, Stranger BE, Cohn SL, Diskin SJ Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017 Feb;72:177-185. doi: 10.1016/j.ejca.2016.11.022
2014-01 Morgenstern D, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada J, Ambros PF, Matthay KK, Cohn SL, Pearson ADJ, Irwin M Prognostic significance of specific metastatic sites in patients with stage 4 neuroblastoma Eur J Cancer. 2016 Sep;65:1-10. doi: 10.1016/j.ejca.2016.06.005
2013-03 Moroz V,  Machin D,  Hero B, Ladenstein R, Berthold F, Kao P, Obeng Y,  Pearson ADJ, Cohn SL, London WB

The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project

Pediatr Blood Cancer. 2020 May 30. doi: 10.1002/pbc.28359

2013-02 Kirby C, Andrade J, Huang L, Nakazawa A, Matthay KK, Ambros PF, Leuschner I, Park JR, London WB, Pearson ADJ, Cohn SL, Volchenboum SL Gene expression analysis of neuroblastoma tumors according to MKI and differentiation status Presented at ANR 2014.
2013-01 Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG. Biologic, clinical, and prognostic differences based upon primary site of origin in neuroblastoma J Clin Oncol. 2014 Oct 1;32(28):3169-76.
2012-01 Morgenstern DA, London WB, Stephens D, Volchenboum SL, Hero B, Di Cataldo A, Nakagawara A, Shimada H, Ambros PF, Matthay KK, Cohn SL, Pearson AD, Irwin MS. Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: a study from the International Neuroblastoma Risk Group (INRG) database J Clin Oncol. 2014 Apr20:32 (12):1228-35
2009-02 Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V, Ladenstein R, De Bernardi B, Rubie H, Berthold F, Matthay KK, Monclair T, Ambros PF, Pearson AD, Cohn SL, London WB. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma Eur J Cancer. 2011 Mar;47(4):561-71
2008-03 London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T, Matthay KK. Clinical and biologic features predictive of survival after relapse of neuroblastoma J Clin Oncol. 2011 Aug 20;29(24):3286-92
2008-02 Angelini P, London WB, Cohn SL, Pearson AD, Matthay KK, Monclair T, Ambros PF, Shimada H, Leuschner I, Peuchmaur M, Irwin MS, Baruchel S Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype Eur J Cancer. 2012 May;48(8):1185-91
2008-01 Taggart DR, London WB, Schmidt ML, DuBois SG, Monclair TF, Nakagawara A, De Bernardi B, Ambros PF, Pearson AD, Cohn SL, Matthay KK. Prognostic Value of the Stage 4S Metastatic Pattern and Tumor Biology in Patients With Metastatic Neuroblastoma Diagnosed Between Birth and 18 Months of Age J Clin Oncol. 2011 Nov 20;29(33):4358-64
2007-03 Schleiermacher G, Mosseri V, London WB, Maris JM, Brodeur GM, Attiyeh E, Haber M, Khan J, Nakagawara A, Speleman F, Noguera R, Tonini GP, Fischer M, Ambros I, Monclair T, Matthay KK, Ambros P, Cohn SL, Pearson AD Segmental chromosomal alterations have prognostic impact in neuroblastoma Br J Cancer. 2012 Oct 9;107(8):1418-22
2007-01 Mossé YP, Deyell RJ, Berthold F, Nagakawara A, Ambros PF, Monclair T, Cohn SL, Pearson AD, London WB, Matthay KK Neuroblastoma Neuroblastoma in older children, adolescents and young adults Pediatr Blood Cancer. 2013 Sep 13. doi: 10.1002/pbc.24777
2006-03 Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, Monclair T, Ambros PF, Cohn SL Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma J Clin Oncol. 2009 Jan 20;27(3):365-70
2006-02 Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR. Outcome for stage 3 neuroblastoma Pediatr Blood Cancer. 2014 Nov;61(11):1932-9.
2006-01 Dubois SG, London WB, Zhang Y, Matthay KK, Monclair T, Ambros PF, Cohn SL, Pearson A, Diller L. Lung metastases in neuroblastoma at initial diagnosis Pediatr Blood Cancer. 2008 Nov;51(5):589-92